We are live on ! Find out more
LENZ icon

LENZ Therapeutics

3.49 USD
+0.28
8.72%
At close Updated Oct 29, 4:00 PM EDT
Pre-market
After hours
3.31
-0.18
5.16%
1 day
8.72%
5 days
8.05%
1 month
-9.59%
3 months
-38.99%
6 months
-61.44%
Year to date
-78.19%
1 year
-88.61%
5 years
-96.09%
10 years
-97.31%
 

About: LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

Employees: 152

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 13%
Neutral 82.6%
Negative 4.3%
Neutral
Seeking Alpha
15 hours ago
LENZ Therapeutics, Inc. (LENZ) Q3 2026 Earnings Call Transcript
LENZ Therapeutics, Inc. ( LENZ ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Daniel Chevallard - CFO, Principal Financial & Accounting Officer Evert Schimmelpennink - President, CEO, Secretary & Director Shawn Olsson - Chief Commercial Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Alyssa Larios - Leerink Partners LLC, Research Division Yigal Nochomovitz - Citigroup Inc. Exchange Research Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Jason Gerberry - BofA Securities, Research Division Matthew Caufield - H.C.
LENZ Therapeutics, Inc. (LENZ) Q3 2026 Earnings Call Transcript
Positive
MarketBeat
17 hours ago
LENZ Therapeutics Q3 Earnings Call Highlights
LENZ Therapeutics NASDAQ: LENZ reported third-quarter 2026 product revenue of $2.6 million, up 50% sequentially, as prescriptions for its presbyopia eye drop VIZZ increased following the expansion of national advertising and the launch of a telehealth channel.
LENZ Therapeutics Q3 Earnings Call Highlights
Negative
Zacks Investment Research
1 day ago
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to a loss of $0.59 per share a year ago.
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
1 day ago
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
Neutral
GlobeNewsWire
8 days ago
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results.
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
Neutral
GlobeNewsWire
23 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Neutral
PRNewsWire
28 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Neutral
GlobeNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Neutral
GlobeNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Price charts implemented using Lightweight Charts™